A digital health program combined with an activity tracker to improve llifestyle behavior.
Recruiting
- Conditions
- HbA1c, diabetes type 2, lifestyle behavior, activity monitoring, feedback. Leefstijl, zelfmeting van beweging, feedback.
- Registration Number
- NL-OMON28551
- Lead Sponsor
- Hanze University of Applied Sciences, research group Healthy ageing, Allied health care and Nursing.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 96
Inclusion Criteria
People with type 2 diabetes
- Most recent HbA1c-value ≥ 58 mmols/mol (7.5%)
Exclusion Criteria
- Pregnancy
- Already exercising more than 3 hours per week
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c.
- Secondary Outcome Measures
Name Time Method Mood (Pick A Mood; PAM)<br /><br>Motivational questionnaire (measured in four determinants: intention, attitude, self-efficacy and social norm) <br /><br>Physcial activity (measured by the Fitbit, and by the 1-item questionnaire)<br /> <br>BMI<br /><br>Waist and hip circumference (cm)<br /><br>Compliance use of the digital health program<br /><br>Use of the Fitbit Zip <br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie improved blood glucose regulation in type 2 diabetes through digital health interventions and activity trackers?
How does the digital health program in NL-OMON28551 compare to standard-of-care lifestyle interventions for type 2 diabetes management?
Are there specific biomarkers associated with successful lifestyle behavior modification in type 2 diabetes patients using activity monitoring feedback?
What adverse events are commonly reported in type 2 diabetes trials using activity trackers and digital health programs, and how are they managed?
What combination approaches or competitor drugs are being explored alongside lifestyle interventions for HbA1c reduction in type 2 diabetes patients?